VR goggles may ease anxiety and improve sleep for COPD patients in the ICU

NCT ID NCT07475650

Completed Symptom relief Sponsor: TC Erciyes University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether using virtual reality (VR) glasses for 30 minutes each evening could improve sleep quality, reduce anxiety, and stabilize vital signs in intensive care patients with COPD. Fifty patients were split into two groups: one received VR sessions for a week, the other received standard care. Sleep and anxiety were measured using standard scales, and vital signs were tracked before and after each session.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: virtual reality glasses
What this could lead to: If it works, this could offer a simple, drug-free way to help ICU patients with COPD sleep better and feel less anxious during their hospital stay.
What could go wrong: This is a small, completed study with only 50 participants. The results may not apply to all COPD patients or other hospital settings. The effect may be modest and not a substitute for medical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder chronic obstructive pulmonary disease COPD, severe early onset insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANXIETY COPD SLEEP QUALITY OF ICU PATIENTS

Contacts and locations

Locations

Faculty of Health Sciences Erciyes University

Kayseri, Melikgazi, 38260, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.